An unusual precipitant of acute heart failure—ANCA-associated vasculitis in a patient with ischaemic cardiomyopathy: a case report

Krishna Prasad, Pruthvi C. Revaiah, Krishna Santosh Vemuri, and Parag Barwad *

Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education & Research, Sector 12, Chandigarh 160012, India

Received 29 November 2019; first decision 22 January 2020; accepted 9 September 2020; online publish-ahead-of-print 5 November 2020

Background
Antineutrophil cytoplasmic antibody (ANCA)-associated pulmonary renal vasculitis is an uncommon disease entity. Its presentation as acute heart failure for the first time in a patient with established coronary artery disease (CAD) is even rarer. We present here a case of such an association and an approach to managing this clinical situation.

Case summary
A 60-year-old male patient presented to the emergency room with recent-onset dyspnoea New York Heart Association Class IV. He was having hypertension, uncontrolled diabetes mellitus, chronic kidney disease (CKD), and CAD. He also underwent a percutaneous coronary intervention to left anterior descending in the past for acute coronary syndrome and had moderate left ventricular dysfunction. He was being managed as a case of acute decompensated heart failure (ADHF) and was mechanically ventilated. Suddenly his ventilator requirement increased and endotracheal aspirate contained blood. The chest radiograph showed bilateral hilar infiltrates. Simultaneously he also had recurrent episodes of ventricular tachycardia (VT) requiring direct current (DC) cardioversion. Blood investigations showed deranged renal function and severe hyperkalaemia, but no evidence of coagulopathy. High-resolution computed tomography chest showed features of diffuse alveolar haemorrhage. Further investigations revealed high titres of c-ANCA and raised inflammatory biomarkers. A diagnosis of ANCA-associated vasculitis presenting as acute on CKD with dyselectrolytaemia (hyperkalaemia) leading to VT was made. Apart from standard management for associated illness, he was treated with plasma exchange, steroids, and cyclophosphamide to which he responded and was later on discharged.

Discussion
Antineutrophil cytoplasmic antibody-related pulmonary renal vasculitis can lead to rapidly progressing renal failure and may present as ADHF in a patient with existent CAD. The associated VT storm in our patient can be attributed to hyperkalaemia secondary to acute renal failure. A multidisciplinary approach is required for the successful management of such a complex clinical scenario.

Keywords
Antineutrophil cytoplasmic antibodies-associated vasculitis • Coronary artery disease • Renal failure • Diffuse alveolar haemorrhage • Ventricular tachycardia storm • Case report

* Corresponding author. Tel: +91 8968732470, Email: paragaims@gmail.com
Handling Editor: Sinning Christoph
Peer-reviewers: Hatipoglu Suzan; Ang Richard; Cinier Goksel; Enache Bogdan; Jonathan M. Behar
Compliance Editor: Stefan Simovic
Supplemental Material Editor: Patel Peysh A.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Learning points

- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a rare diagnosis which requires a high index of suspicion and can precipitate heart failure in patient with underlying heart disease.
- Hyperkalaemia in combination with hypoxaemia and acidosis can precipitate ventricular tachycardia in a previously scarred myocardium.
- A multidisciplinary team approach is essential for successful management of patients with ANCA vasculitis and heart failure.

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a rare disease entity and its occurrence for the first time in a patient with established coronary artery disease (CAD) and presenting as acute heart failure is even rarer. A high index of suspicion is needed for making such a diagnosis and every other possibility needs to be ruled out before embarking upon such an association. This is because the treatment of such aggressive vasculitis involves aggressive immunosuppression and may have a serious implication on existent CAD status. Here we report a case of ANCA-associated pulmonary renal vasculitis presenting for the first time as acute decompensated heart failure (ADHF) complicated by ventricular tachycardia (VT) storm in a patient with CAD and an approach to management in such cases.

Timeline

2000 Anterior wall myocardial infarction
Percutaneous angioplasty to left anterior descending coronary artery done
Left ventricular ejection fraction: 40%
Creatinine: 1.2 mg/dL

2018 Hospital admission for heart failure with acute kidney injury

Day 1 Hyperkalaemia and multiple episodes of haemodynamically unstable ventricular tachycardia. Direct current cardioversion, amiodarone infusion, and sustained low-efficiency dialysis given

Day 2 Blood in endotracheal tube and haemoglobin drop; diffuse alveolar haemorrhage confirmed (DAH)

Day 3 Antineutrophil cytoplasmic antibody (ANCA) by indirect immunofluorescence and ELISA—positive and diagnosed as ANCA-associated vasculitis, high-resolution computed tomography chest suggestive of DAH

Day 4 Plasma exchange therapy and immunosuppression under cover of antibiotics started

Day 10 Patient improved and discharged home. Counselling for automated implantable cardioverter-defibrillator insertion, refused by attendants

Day 11 Cyclophosphamide pulse therapy continued for 6 months. Patient remained dialysis dependent

9 months Patient had a sudden cardiac arrest during renal replacement therapy

Case presentation

A 60-year-old male presented to the emergency room (ER) of our hospital with recent-onset New York Heart Association (NYHA) Class IV dyspnoea. He had hypertension (HT) and uncontrolled diabetes mellitus (DM) for the past 20 years. He also had an acute coronary event 18 years ago for which he underwent coronary angiography and stenting was performed to left anterior descending (LAD) artery. His last documented left ventricular ejection fraction (LVEF) before this event was 35–40% with severe hypokinesia involving the LAD territory. He was on aspirin, statin, and beta-blocker for CAD; oral hypoglycaemic drugs, and insulin for DM and angiotensin-converting enzyme inhibitor for HT. His clinical status deteriorated rapidly from NYHA II to IV in the last 4 days before presentation at ER. On examination, he had a heart rate of 130/min, blood pressure of 170/90 mmHg, respiratory rate of 30/min, systemic oxygen saturation of 70% on room air, and raised jugular venous pressure. Auscultation revealed fine basal crepitation and left ventricular (LV) third heart sound. Echocardiogram showed an LVEF of 35% with regional wall motion abnormality in LAD territory. N-terminal prohormone of brain natriuretic peptide levels were 8923 pg/mL. With the above history, he was initially managed as ADHF with non-invasive ventilation, diuretics, and vasodilators.

Electrocardiogram (ECG) showed sinus tachycardia, Q waves in anterior leads (Figure 1). However, no new ST-T changes were noticed in comparison with his previous ECG. Serial cardiac biomarkers (Troponin I and CK MB) were in the normal range. Blood investigations showed anaemia (haemoglobin of 10.4 g/dL), hyperkalaemia (6.9 mEq/L), deranged renal function (serum creatinine—6.7 mg/dL and blood urea nitrogen—46 mg/dL), and poor glycaemic control (HbA1c of 8.9%). Arterial blood gases analysis showed hypoxaemia (PaO2 of 60%) and metabolic acidosis (pH of 7.22). Urine analysis showed active sediments (3–5 red blood cells/high power field) and proteinuria (24-h urine protein of 1.4 g/day). A chest radiograph showed pulmonary oedema with bilateral pleural effusion (Figure 2).

He was managed with anti-hyperkalaemic measures (insulin-dextrose infusion, salbutamol nebulization, oral potassium binders). Despite the above measures, his hyperkalaemia was persistent. Later in the course, he had multiple episodes of haemodynamically unstable monomorphic VT (Figure 3) in <3 h duration requiring electrical cardioversion supplemented with intravenous amiodarone. He was mechanically ventilated due to worsening respiratory symptoms and hypotension. Sustained low-efficiency dialysis was also performed for 8 h on Day 1.

On Day 2 of admission, he had increasing requirements of oxygen (FiO2) and endotracheal tube suction showed bloodstained secretions. There was also a haemoglobin drop of ~5 g/dL (10.4–5.4 g/dL).
High-resolution computed tomography was performed to find the cause of bleeding, which showed diffuse bilateral perihilar consolidation and areas of ground-glass opacities predominantly involving the dependent lobes suggestive of diffuse alveolar haemorrhage (DAH) (Figure 4). Taking into consideration a new onset of renal dysfunction and DAH, a possibility of active vasculitis was kept and an immunology consultation was taken.

Subsequent investigations showed strongly positive c-ANCAs (ELISA and indirect immunofluorescence). Antinuclear antibodies and anti-glomerular basement membrane antibodies were negative.

Based on the above results, a diagnosis of ANCA-associated pulmonary renal vasculitis precipitating acute heart failure was made. Refractory hyperkalaemia and severe metabolic acidosis (secondary to acute kidney injury) combined with hypoxaemia and heart failure, precipitated the VT storm in an already scarred myocardium. In addition to the treatment of heart failure, he was started on immunosuppression (methylprednisolone pulse therapy—1 g daily for 3 days) and seven sessions of plasma exchange.

With the above measures, the patient improved significantly and could be extubated 3 days later. Renal biopsy was initially deferred as

Figure 1 Baseline electrocardiogram showing normal sinus rhythm with qs pattern in leads V1 and V2 with left axis deviation.
he was on dual antiplatelets (clopidogrel was added at admission) and later on because of anticipated technical difficulties (the patient being obese). He was also started on intravenous cyclophosphamide (10 mg/kg/dose), initially every 2 weeks for the first three doses followed by every 3 weeks for the next 6 months.

At 6 months follow-up, he was doing well from a cardiac point of view with LVEF of 40% and NYHA II functional status. However, his renal function deteriorated further requiring renal replacement therapy (RRT). He was also counselled about the need for an intracardiac defibrillator for the prevention of sudden cardiac death which he refused because of financial constraints. A telephonic follow-up performed at 9 months revealed that he had a sudden cardiac arrest and died during a session of dialysis.

Discussion

The spectrum of ANCA-associated vasculitis includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic GPA (Churg-Strauss syndrome).\textsuperscript{1} It is an autoimmune disorder affecting small and medium-sized vessels. It usually presents as fatigue, fever, weight loss, arthralgias, rhinosinusitis, cough, dyspnoea, urinary abnormalities, purpura, and neurologic dysfunction.\textsuperscript{2} Cardiac manifestations in ANCA-associated vasculitis are known to occur in \~3.3–90% in various cohorts depending on the method of evaluation and diagnostic tests applied.\textsuperscript{3–5} Pericarditis is the most common manifestation (35%), followed by cardiomyopathy (30%), CAD (12%), valvular disease (6%), concomitant CAD and valvular disease (6%), concomitant pericarditis and cardiomyopathy (1.6%), and severe conduction disorders (1.6%).\textsuperscript{4} Ventricular arrhythmias and particularly VT storm due to active vasculitis are rarely observed in ANCA-associated vasculitis. It has been reported in only two cases in the past and both patients had histopathological evidence of

Figure 2 Chest X-ray showing bilateral diffuse infiltrates predominantly perihilar in location.

Figure 3 Electrocardiogram showing monomorphic ventricular tachycardia.
myocarditis. In the report by Santos et al., a 44-year-old female with GPA developed sustained VT preceded by bradycardia which improved after temporary pacing followed by a permanent pacemaker insertion. In another report by Hanna et al., a patient with a history of recurrent otitis media presented with myocarditis, renal dysfunction, hyperkalaemia, and VT. She was treated with corticosteroids, cyclophosphamide, and plasma exchange. She showed significant improvement with treatment and her renal biopsy was suggestive of pauci-immune glomerulonephritis. Our patient differs entirely from the previous reports by the presence of pre-existent CAD. The initial presentation as ADHF made us treat him in those lines until his clinical status deteriorated because of VT storm and DAH. We also postulate that the substrate for VT storm in our patient was likely due to previously scarred myocardium as the VT morphology was monomorphic. Hyperkalaemia in the background of acidosis and hypoxaemia precipitated the VT storm in our patient. Hypoxia and acidosis may lead to global ventricular ischaemia and when combined with hyperkalaemia can promote phase 2 re-entry by further increasing repolarization reserve in epicardial ventricular tissue and thus predisposing to VT. Myocarditis being an aetiology of VT is unlikely as cardiac biomarkers were negative and there was no new LV dysfunction. However, this cannot be conclusively ruled out as cardiac magnetic resonance imaging was not performed. Also, the clinical features, ECG, and cardiac enzymes did not suggest acute coronary syndrome and thus, we did not perform coronary angiography. Though we could not get a histopathological diagnosis by renal biopsy; presence of active sediments in urine, rapidly progressive renal failure, evidence of DAH, and presence of ANCA positivity essentially established the diagnosis of ANCA-associated vasculitis. The dramatic response to steroids and plasma exchange further substantiated our diagnosis. Overall our case describes acute heart failure and VT as an uncommon first presentation of ANCA-related pulmonary renal vasculitis in a patient with pre-existing heart disease.

**Conclusion**

Antineutrophil cytoplasmic antibody-associated vasculitis rarely may present as ADHF in a patient with pre-existing LV dysfunction. A multidisciplinary approach is vital for diagnosis and successful treatment.

**Supplementary material**

Supplementary material is available at European Heart Journal - Case Reports online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

**Consent:** The author’s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

**Conflict of interest:** none declared.

**References**

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.
2. Falk RJ, Hogan S, Carey TS, Jennette JC. The clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990;113:656–663.
3. Morelli S, Gugno Di Castelmenardo AM, Conti F, Sgreccia A, Alessandri C, Bernardo ML et al. Cardiac involvement in patients with Wegener’s granulomatosis. Rheumatol Int 2000;19:209–212.
4. McGech L, Carette S, Cuthbertson D, Hoffman GS, Khalidi N, Koenig CL et al. Cardiac involvement in granulomatosis with polyangiitis. J Rheumatol 2015;42:1209–1212.
5. Oliveira GH, Seward JB, Tsang TS, Specks U, eds. Echocardiographic findings in patients with Wegener granulomatosis. Mayo Clin Proc 2003;78:1435–1440.
6. Santos LPS, Bomfim VG, Bezerra CF, Costa NV, Carvalho RBP, Carvalho RS et al. Heart conduction system defects and sustained ventricular tachycardia...
complications in a patient with granulomatosis with polyangiitis. A case report and literature review. *Rev Bras Ter Intensiva* 2017;29:386.

7. Hanna RM, Lopez E, Wilson J. Granulomatosis with polyangiitis with myocarditis and ventricular tachycardia. *Case Rep Med* 2017;2017:1–6.

8. Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. *Circ Arrhythm Electrophysiol* 2017;10:e004667.

9. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. *Arthritis Rheum* 2010;33:1101–1107.